Literature DB >> 16875815

Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).

Da-Eun Chung1, Felix Kratz.   

Abstract

A water-soluble albumin-binding prodrug of doxorubicin [EMC-Gly-Gly-Gly-Arg-Arg-DOXO (EMC, 6-maleimidocaproic acid)] was developed that is cleaved specifically by the tumor-associated protease urokinase-type plasminogen activator (uPA).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16875815     DOI： 10.1016/j.bmcl.2006.07.023

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

1.  Urokinase-controlled tumor penetrating peptide.

Authors:  Gary B Braun; Kazuki N Sugahara; Olivia M Yu; Venkata Ramana Kotamraju; Tarmo Mölder; Andrew M Lowy; Erkki Ruoslahti; Tambet Teesalu
Journal:  J Control Release       Date:  2016-04-19       Impact factor: 9.776

2.  Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.

Authors:  Bakheet Elsadek; Ralph Graeser; André Warnecke; Clemens Unger; Tahia Saleem; Nagla El-Melegy; Hafez Madkor; Felix Kratz
Journal:  ACS Med Chem Lett       Date:  2010-05-26       Impact factor: 4.345

Review 3.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors:  Zhibo Liu; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

4.  Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Authors:  Silke Metz; Christian Panke; Alexander K Haas; Jürgen Schanzer; Wilma Lau; Rebecca Croasdale; Eike Hoffmann; Britta Schneider; Johannes Auer; Christian Gassner; Birgit Bossenmaier; Pablo Umana; Claudio Sustmann; Ulrich Brinkmann
Journal:  Protein Eng Des Sel       Date:  2012-09-13       Impact factor: 1.650

5.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

6.  Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.

Authors:  Anna Kwiatkowska; Frédéric Couture; Samia Ait-Mohand; Roxane Desjardins; Yves L Dory; Brigitte Guérin; Robert Day
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

7.  Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy.

Authors:  Zhiyang Cheng; Ying Huang; Pingxuan Shao; Lei Wang; Shulei Zhu; Jiahui Yu; Wei Lu
Journal:  ACS Omega       Date:  2021-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.